Sagility Buy Call: Elara Sees 26% Upside in 2026

Coverage initiation and why it matters

Elara Capital has initiated coverage on Sagility, a healthcare-focused technology provider, with a Buy rating. The brokerage’s thesis rests on sustained cost pressure for healthcare payers, which it says is expanding outsourcing opportunities. Elara also points to Sagility’s end-to-end capabilities across the payer value chain and what it describes as further account-mining scope within the company’s top-10 clients. Sagility has more than 80 clients, and its top five largest clients have an average tenure of 18 years. Elara expects this combination of long relationships and deeper wallet-share potential to support multi-year growth.

Target price, valuation framework, and implied upside

Elara has set a target price of ₹54, valuing Sagility at 19x FY28E EPS. The target implies a potential upside of about 26% from the April 17, 2026 closing level of ₹43 on the NSE. During the session cited, Sagility shares were trading at ₹42.28 around 02:20 PM, down 1.51%, after hitting an intraday low of ₹42.14. The broader market was relatively steady, with the NSE Nifty50 at 24,392, up 38.45 points or 0.16%. Elara also noted the stock was trading at 15.2x FY28E EPS, which it called a discount to some peers.

Growth expectations: revenue and earnings CAGRs

Elara expects Sagility to report revenue and earnings CAGRs of 13.9% and 20.0%, respectively, in INR terms over FY26E to FY28E. It also models USD and INR revenue CAGRs of 12.4% and 13.9% over FY26E to FY28E. The brokerage attributed the growth outlook largely to FTE additions, with only modest gains in revenue per employee. Elara expects the revenue mix to remain broadly unchanged in the medium term. Separately, the company has guided for 22.5% revenue growth in FY26 and low-to-mid teen growth over the medium term, which Elara said appears achievable.

Client concentration: a key debate for investors

Sagility’s revenue concentration is central to the investment debate. As of the trailing twelve months (TTM) ended December 2025, the company generated 60%, 71%, and 85% of revenue from its top 3, 5, and 10 clients, respectively. Elara said concerns around client concentration and scalability of key accounts are likely contributing to the valuation discount. At the same time, the brokerage views those concerns as overstated, arguing that there is ample scope to scale up within existing large accounts. How quickly that scale-up materialises will matter for both growth durability and market re-rating.

How Elara sizes the scale-up opportunity in top accounts

To assess long-term potential in key accounts, Elara highlighted revenue from the top three clients at USD 465 million (TTM ended December 2025). It sees scope for a further 40% increase, particularly from clients 2 and 3. Revenue from the top five clients was USD 550 million over the same period, with Elara estimating it could be scaled up by 80% to 90%. The brokerage said the largest opportunities are in clients 3, 4, and 5. The numbers are presented as a way to show that concentration risk can coexist with meaningful headroom in the same accounts.

Industry context: why payers may outsource more

Elara’s thesis is linked to operating stress among US healthcare payers. It said medical loss ratios (claims paid to premium earned) are increasing across payers such as United Healthcare, Humana, CVS Aetna, Elevance Health, Cigna HC, and Centene Corp. It also said administrative costs have risen steadily, growing at a 2.5% to 18% CAGR over the past decade. In that environment, Elara expects payers to pursue further cost takeout through outsourcing. For vendors like Sagility, this backdrop is important because it can support both new workstreams and deeper penetration in existing contracts.

Margins, Broadpath integration, and debt repayment

Elara expects adjusted EBITDA margins to face some pressure in FY26E due to integration of the lower-margin Broadpath business. Beyond that, it expects margins to stabilise around 25% by FY28E. The brokerage also expects earnings to rise sharply by FY28E, aided by the absence of finance costs following planned debt repayment in FY27E. This sequencing matters because it links earnings growth not only to revenue expansion but also to changes in the cost structure. Elara’s model implicitly relies on execution around integration and deleveraging to play out as planned.

Market data points cited alongside the call

The article data also lists several market and performance indicators for Sagility. It cites a market capitalisation of ₹201,160 million (₹20,116 crore) and a current market price (CMP) of ₹43, with a 52-week high of ₹57.9 and low of ₹35.8. It lists a P/E of 23.1x, book value of ₹19, ROCE of 9.58%, and ROE of 7.38%. For the TTM ended December 2025, it reports USD revenue of USD 773.6 million, adjusted EBITDA of USD 199.2 million, and adjusted PAT of USD 122.1 million. It also reports INR PAT of ₹10,634 million for the same TTM period.

What brokerages flag as key risks

Elara’s key risk is that any decline in medical loss ratios and administrative costs for payers could reduce outsourcing demand. The brokerage’s positive view depends on continued cost pressure at payers translating into sustained demand for third-party delivery and process optimisation. Another market concern it references is client concentration, even as it argues there is headroom to scale top accounts. Separately, the data provided notes promoter shareholding changes, stating that EQT (the promoter) sold 16.4% stake, reducing holding to 50.95%, while FII holding rose from 3.39% to 10.25% and DII holding rose from 7.47% to 21.36%. These are positioning datapoints, but they do not remove the underlying operational risks highlighted by Elara.

Key facts table

Client concentration and account headroom (TTM Dec 2025)

Conclusion

Elara’s initiation frames Sagility as a beneficiary of outsourcing demand driven by cost pressure in US healthcare, while also focusing on the company’s ability to scale within its largest accounts. The call builds on a target price of ₹54 and a valuation of 19x FY28E EPS, implying about 26% upside versus the cited ₹43 close. Near-term watchpoints include Broadpath integration effects on margins, the trajectory toward planned debt repayment in FY27E, and whether account mining can offset concentration concerns. Investors will likely track execution against FY26 guidance of 22.5% revenue growth and the brokerage’s FY26E to FY28E growth expectations.